Researchers at North Carolina-based Locus Biosciences think they have a potential cure for antibiotic resistance using CRISPR’s lesser-known Cas3 enzyme. Most of the interest in CRISPR ...

Enter Cas3. This latest enzyme is a different beast altogether, for a number of reasons. First and foremost is its ravenous appetite for DNA sequences, allowing scientists to shred large segments ...

Other methods can then be used to insert new DNA. But the new CRISPR-Cas3 system adapted by the UCSF scientists is different. The key enzyme in this system, Cas3, removes much longer stretches of ...

The new system, called CRISPR-Cas3, can efficiently erase long stretches of DNA from a targeted site in the human genome, a capability not easily attainable in more traditional CRISPR-Cas9 systems.

The type I CRISPR protein Cas3 works like Pac-Man, chomping away at a continuous stream of nucleotides with intrinsic activity for introducing targeted large deletions from a few hundred base ...

Design by Evelyn Mousigian. Buy this photo. The CRISPR-Cas3 system, the focus of the U-M paper, is much less researched than Cas9. Despite this, Rackham student Mason Myers, one of the lead authors on ...

The new technique is called CRISPR-Cas3 — usually, when you hear about CRISPR tech, it's the Cas9 variety — and Cornell researchers believe it could be used to cure viral diseases, according ...

Based in North Carolina’s Research Triangle, the startup recently announced promising phase 1b clinical trial results for their use of CRISPR-Cas3-enhanced bacteriophages as a treatment for ...

"Dual CRISPR-Cas3 is a promising tool to induce a gigantic genomic deletion and restore dystrophin protein via multi-exon skipping induction," says senior author Akitsu Hotta of Kyoto University.

The new system, called CRISPR-Cas3, can efficiently erase long stretches of DNA from a targeted site in the human genome, a capability not easily attainable in more traditional CRISPR-Cas9 systems.